Press release
Adult Malignant Glioma Therapeutics Market Projected to Reach from US$ 1.3 Bn to US$ 2.9 Billion by 2026 with a 9.2% CAGR | Exclusive Report By TMR
Adult Malignant Glioma Therapeutics
Get Sample PDF Brochure from here: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=13211
Understanding Adult Malignant Glioma Therapeutics
Malignant gliomas, including glioblastoma multiforme (GBM) and anaplastic astrocytoma, are primary brain tumors in adults characterized by rapid growth and resistance to treatment. Therapeutics include chemotherapy (e.g., temozolomide), targeted therapies (e.g., bevacizumab), radiation-enhancing agents, and emerging immunotherapies. The market's 2017 valuation of US$1.3 billion highlights its established foundation, with the projected rise to US$2.9 billion by 2026 emphasizing its growing importance amid limited survival outcomes and evolving treatment paradigms.
The 9.2% CAGR signals a dynamic growth phase, fueled by innovation and unmet medical needs. Gliomas' complexity drives a robust therapeutic pipeline, ensuring sustained market momentum.
Key Drivers of Market Growth
Several factors are propelling the adult malignant glioma therapeutics market toward its US$2.9 billion valuation by 2026. First, the rising incidence of brain tumors is a key driver. Aging populations and improved diagnostics-like MRI and molecular profiling-are increasing detection rates, with GBM being the most common and lethal form. This growing patient pool, coupled with high mortality, fuels demand for novel therapies, aligning with the market's 9.2% CAGR.
Second, advancements in treatment modalities are accelerating growth. Beyond standard chemoradiation, targeted therapies inhibiting angiogenesis (e.g., VEGF inhibitors) and tumor growth pathways (e.g., EGFR inhibitors) offer new hope. Immunotherapies, including checkpoint inhibitors and personalized vaccines, are gaining traction, supported by breakthroughs in understanding glioma immunology. These innovations drive the market toward US$2.9 billion, addressing resistance to conventional treatments.
Third, increased R&D investment and regulatory support are boosting the market. Pharmaceutical companies, backed by government grants and fast-track designations from agencies like the FDA, are prioritizing glioma research. Orphan drug status for rare cancers incentivizes development, enhancing the pipeline and supporting the market's significant growth trajectory through 2026.
Leading Players:
Merck & Co. Inc.
F. Hoffmann-La Roche Ltd.
Arbor Pharmaceuticals
Pfizer Inc.
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Company
Sun Pharmaceuticals Ltd.
Teva Pharmaceutical Industries Limited
and Emcure Pharmaceuticals Limited.
Visit our report to discover essential insights and analysis - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=13211
Market Segmentation and Regional Insights
The market segments by therapy type, glioma type, and geography. Chemotherapy dominates, led by temozolomide, while targeted therapies and immunotherapies are fast-growing segments due to precision and efficacy. GBM holds the largest share, reflecting its prevalence, with anaplastic gliomas as a smaller but critical subset. Distribution occurs via hospitals, oncology centers, and pharmacies, with hospitals leading due to complex treatment needs.
Regionally, North America accounted for a significant portion of the US$1.3 billion valuation in 2017, driven by advanced healthcare systems, high R&D spending, and strong patient awareness in the United States. Europe followed, with robust markets in Germany and the UK, supported by universal healthcare. The Asia-Pacific region, however, was poised for the fastest growth through 2026, fueled by rising healthcare access, increasing cancer awareness, and research investments in China and Japan.
Challenges and Opportunities
The market faced challenges during this period. High treatment costs and limited efficacy-median survival for GBM remains under 15 months-restricted adoption. Adverse effects, such as neurotoxicity or immunosuppression, complicated therapy, while regulatory hurdles and small patient populations slowed drug approvals. Generic competition for established drugs also pressured pricing.
These challenges, however, presented opportunities. Companies developing cost-effective alternatives or combination therapies could improve outcomes, supporting the push to US$2.9 billion. Innovations like tumor-treating fields (TTFields) or gene therapies offered potential breakthroughs, while expanding clinical trials in emerging markets broadened access. Partnerships with biotech firms could exceed projections, targeting resistant gliomas.
The Road to 2026
By 2026, the global adult malignant glioma therapeutics market reached its projected US$2.9 billion, reflecting nine years of strong growth at a 9.2% CAGR from US$1.3 billion in 2017. This achievement was driven by rising incidence, therapeutic innovation, and global efforts. As the forecast period concluded, the market's trajectory suggested continued momentum, with potential for immunotherapy and precision medicine to shape future advances.
In conclusion, the adult malignant glioma therapeutics market demonstrated remarkable growth from 2018 to 2026. Rising from US$1.3 billion to US$2.9 billion, it addressed a dire health challenge with transformative potential. Stakeholders-from researchers to pharma firms-played a vital role in this success, ensuring that innovative solutions reached patients through 2026 and beyond.
Explore Latest Research Reports by Transparency Market Research:
Veterinary Ventilators Market: https://www.pharmiweb.com/press-release/2025-03-18/veterinary-ventilators-market-to-surpass-us-13-bn-by-2035-amid-rising-demand-for-advanced-animal-healthcare-solutions-tmr-research
Wearable Pulse Oximeters Market: https://www.pharmiweb.com/press-release/2025-03-18/wearable-pulse-oximeters-market-to-surpass-us-5945-mn-by-2031-amid-rising-demand-for-smart-health-monitoring-solutions-tmr-research
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact Us:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Adult Malignant Glioma Therapeutics Market Projected to Reach from US$ 1.3 Bn to US$ 2.9 Billion by 2026 with a 9.2% CAGR | Exclusive Report By TMR here
News-ID: 3960811 • Views: …
More Releases from Transparency Market Research
Global SiC Ceramics Market Poised for Robust Growth, Projected to Reach USD 3.1 …
The global silicon carbide (SiC) ceramics market continues to demonstrate strong growth potential, underpinned by accelerating demand from advanced industrial and electronic applications. Valued at US$ 1.8 Billion in 2024, the market is projected to reach US$ 3.1 Billion by 2035, expanding at a compound annual growth rate (CAGR) of 5.2% during the forecast period from 2025 to 2035. This steady expansion reflects the increasing importance of SiC ceramics as…
Furfuryl Alcohol Market to Reach USD 1.34 Billion by 2035, Supported by Rising D …
The global Furfuryl Alcohol Market was valued at US$ 624.3 million in 2024 and is projected to reach US$ 1,341.2 million by 2035, expanding at a compound annual growth rate (CAGR) of 7.2% from 2025 to 2035.
This growth is primarily driven by the rising demand for bio-based and sustainable chemicals, along with the steady expansion of the foundry and metal casting industry, particularly across emerging economies in Asia Pacific.
Gain a…
Air-Entraining Agents Market Outlook 2035: Forecast to Reach US$ 2.48 Billion by …
The global Air-Entraining Agents (AEAs) Market was valued at US$ 1.70 billion in 2024 and is projected to reach US$ 2.48 billion by 2035, expanding at a compound annual growth rate (CAGR) of 3.5% from 2025 to 2035. This steady growth trajectory reflects the essential role AEAs play in modern concrete formulations, particularly in infrastructure projects that demand long-term durability, freeze-thaw resistance, and improved workability.
Despite being a mature segment within…
A2P SMS Market Outlook 2035: Expanding from US$ 71.2 Bn in 2024 to US$ 117.0 Bn …
The global Application-to-Person (A2P) SMS market is entering a phase of steady and resilient expansion, driven by the growing need for secure, reliable, and real-time communication between enterprises and consumers. Valued at US$ 71.2 Bn in 2024, the market is projected to reach US$ 117.0 Bn by 2035, expanding at a CAGR of 4.2% from 2025 to 2035. Despite the rise of internet-based messaging platforms, A2P SMS continues to maintain…
More Releases for US$2
Industrial Automation Market to Reach US$345.73 Bn by 2031, Driven by Smart Tech …
✅Industrial Automation Market: Transforming the Future of Manufacturing and Efficiency
Overview of the Market
The global industrial automation market is witnessing a profound transformation driven by the increasing demand for operational efficiency, reduced human intervention, and technological advancements. Valued at US$184.34 billion in 2024, the market is projected to surge to US$345.73 billion by 2031, registering a robust CAGR of 9.4% during the forecast period. This growth reflects the widespread adoption of…
Texturized Vegetable Protein Market Worth US$ 2 Bn by 2029
The global Texturized Vegetable Protein market is estimated to attain a valuation of US$ 2 Bn by the end of 2029, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 6% during the forecast period, 2019 - 2029.
The key objective of the TMR report is to offer a complete assessment of the global market…
N-Methyl-2-Pyrrolidone Market worth US$ 2 Billion by 2027
N-Methyl-2-Pyrrolidone Market: Key Highlights
The N-methyl-2-pyrrolidone (NMP) market was valued at ~US$ 1.1 Bn in 2018, and is anticipated to expand at a CAGR of ~6.0% from 2019 to 2027.
The global N-methyl-2-pyrrolidone market is driven by the rise in the demand for N-methyl-2-pyrrolidone from the electronics industry.
In terms of value, the N-methyl-2-pyrrolidone market in Asia Pacific is expected to expand at a CAGR of ~8% during the forecast period. China is…
N-Methyl-2-Pyrrolidone in Cosmetics worth US$ 2 Billion by 2027
N-Methyl-2-Pyrrolidone Market Holds Multichannel Revenue Opportunities
The sales of consumer electronics are showing no signs of slowing down, implying that, manufacturers of electronic devices are investing toward the development of smart-sized products with better functionalities, which manages to attract the attention of consumers.
Read report Overview-
https://www.transparencymarketresearch.com/n-methyl-2-pyrrolidone-nmpo-market.html
Investments made in the consumer electronics market, are, in turn, creating opportunities for the N-methyl-2-pyrrolidone market, given the rising demand for lithium batteries. According to stats published…
Blockchain Certification Company Lands US $2 Million Investment
Blockchain is growing, the crypto markets are booming but a serious problem which has now started hurting the whole industry is the involvement of a limited number of people who are currently running the show. More than blockchain literacy, we have developers, traders and investors who are driven by misinformation as there is no set standard in the industry to follow.
The whole blockchain is based on open source code and…
Liquid Biopsy Market Worth US$ 2 Billion by 2022
New York, April 24: Market Research Engine has published a new report titled as “Liquid Biopsy Market By Type of Cancer Analysis (Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Liver Cancer); By Product and services Analysis (Instruments, Services and Software, Reagents); By Circulation Biomarkers Analysis (Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs), Circulating Tumor DNA (ctDNA)); By End User Analysis (academic & Research Centers, Reference Laboratories, Hospital and Physician…
